PROCESS FOR PRODUCTION OF NATURAL KILLER CELLS

• US 20120171173A1
• Filed: 09/10/2010
• Published: 07/05/2012
• Est. Priority Date: 09/11/2009
• Status: Active Grant

• Current Assignee: Takara Bio Incorporated (Ningbo Junsheng Investment Group Co., Ltd.)
• Original Assignee: Takara Bio Incorporated (Ningbo Junsheng Investment Group Co., Ltd.)
• Inventors: Enoki, Tatsuji, Ideno, Mitsuko, Yabuuchi, Mie, Jin, Meiko, Sato, Masae, Ashida, Naoko
• Granted Patent: US 9,062,287 B2
• Time in Patent Office: Days
• US Class Current: 424/93.7
• CPC Class Codes: A61K 2035/124 the cells being hematopoietic, bone marrow derived or blood cells
• CPC Class Codes: A61K 2239/31 characterized by the route of administration
• CPC Class Codes: A61K 2239/38 characterised by the dose, timing or administration schedule
• CPC Class Codes: A61K 2239/55 Lung
• CPC Class Codes: A61K 39/4613 Natural-killer cells [NK or NK-T]
• CPC Class Codes: A61K 39/4644 Cancer antigens
• CPC Class Codes: A61P 31/06 for tuberculosis
• CPC Class Codes: A61P 31/10 Antimycotics
• CPC Class Codes: A61P 31/18 for HIV
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: C12N 2500/72 from bacteria
• CPC Class Codes: C12N 2501/2302 Interleukin-2 (IL-2)
• CPC Class Codes: C12N 2501/24 Interferons [IFN]
• CPC Class Codes: C12N 2501/515 CD3, T-cell receptor complex
• CPC Class Codes: C12N 2502/1114 T cells
• CPC Class Codes: C12N 5/0646 Natural killers cells [NK], NKT cells

Abstract

A process for producing a cell mass containing natural killer cells, characterized by involving a step of carrying out the expansion culture of a cell mass containing natural killer cells and/or cells capable of being differentiated into natural killer cells in the presence of a biological response modifier and cells that has been so treated as to lose a proliferation capability, and others.

Claims

1. A process for preparing a cell population containing a natural killer cell, comprising a step of expansion-culturing a cell population containing a natural killer cell and/or a cell capable of differentiating into a natural killer cell, in the presence of a bioresponse modifying agent and a cell which has been subjected to a treatment of diminishing the proliferation ability.

2. The process according to claim 1, wherein the bioresponse modifying agent is a bacterium-derived preparation.

3. The process according to claim 2, wherein the bioresponse modifying agent is a preparation derived from a bacterium selected from the group consisting of OK-432, BCG, Streptcoccus pyogenes, Corynebacterium parvum and a cell wall skeleton thereof.

4. The process according to claim 1, wherein the cell which has been subjected to a treatment of diminishing the proliferation ability is a cell selected from the group consisting of a peripheral blood mononuclear cell, a T cell, a T cell subset and a B cell which has been subjected to a treatment of diminishing the proliferation ability.

5. The process according to claim 4, wherein the cell which has been subjected to a treatment of diminishing the proliferation ability is an artificially expansion-cultured T cell which has been subjected to a treatment of diminishing the proliferation ability.

6. The process according to claim 1, wherein the cell which has been subjected to a treatment of diminishing the proliferation ability is a cell derived from the same individual as that of the natural killer cell or the cell capable of differentiating into a natural killer cell.

7. The process according to claim 1, wherein the step of expansion-culture in the presence of a cell which has been subjected to a treatment of diminishing the proliferation ability comprises performing addition of the cell plural times.

8. The process according to claim 1, wherein a peripheral blood mononuclear cell is used as the natural killer cell and/or the cell capable of differentiating into a natural killer cell.

9. A cell population obtained by the process according to claim 1.

10. A medicament containing the cell population according to claim 9.

11. The cell population according to claim 9, which is for use in treatment of a disease.

12. A method of treating or preventing a disease, comprising a step of administering an effective amount of the cell population according to claim 9 to a subject.